The National Comprehensive Cancer Network (NCCN) released an update to its guideline for B-cell lymphomas.
In the section for follicular lymphoma with histologic transformation to diffuse large B-cell lymphoma (DLBCL) after multiple lines of prior therapy, selinexor was added as a category 2A recommendation only after at least two lines of systemic therapy.
Under the suggested treatment regimens for follicular lymphoma in the second-line and subsequent therapy setting, tazemetostat was added as a category 2A recommendation for two indications: EZH2 mutation-positive relapsed/refractory disease after two prior therapies, and EZH2 wild type relapsed/refractory disease in patients who do not have any satisfactory alternative treatment options.
Lastly, in the section for DLBCL, a new therapy is listed for third-line and subsequent therapy – including patients with disease progression after transplant or CAR T-cell therapy. Selinexor is now recommended as a category 2A recommendation only after at least two lines of systemic therapy.—Zachary Bessette